CML treatment is based on tyrosine kinase inhibitors, which antagonize the constitutively active BCR-ABL tyrosine kinase produced by the Philadelphia chromosome67. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.